Morphological and Functional Changes in Hepatic System Precipitate Liver Disease in Elderly: Addressing Knowledge Gaps and Treatment Challenges
), Ulfa Kholili(2),
(1) Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia
(2) Gastroentero-Hepatology Division, Department of Internal Medicine, Faculty of Medicine-Dr. Soetomo Teaching Hospital, Universitas Airlangga, Surabaya 60131, Indonesia
Corresponding Author
Abstract
Globally, the elderly population are more increasing each year. The enhancement of life expectancy is also followed by the enhancement of chronic illness, which one of them is liver disease. In elderly, there are also several physiological and biochemical changes in liver. Several studies show that the reduction of liver function will affect the severity of liver clinical manifestation in older people. This review article aims to discuss more about liver disease in older population. Hepatitis A in elderly has higher mortality and morbidity rates compared to young people. More over, the progressivity of acute hepatitis B to chronic hepatitis B is also greater in older people than young people. The treatments of hepatitis B and hepatitis C are safe and effective to be applied in elderly. Polypharmacy and fraility affects the elderly to be more susceptible to drug induced liver injury (DILI). This review aims to address knowledge gaps in understanding the morphological and functional changes in the aging hepatic system, their implications for disease progression, and the effectiveness of current therapeutic strategies. By critically analyzing recent evidence, we identify challenges in treating liver diseases in the elderly and highlight areas requiring further research.
Keywords
References
United Nations, Department of Economic and Social Affairs, Population Division. World population ageing, 2019 highlights. 2020.
Badan Pusat Statistik."Jumlah Penduduk Lanjut Usia 2021".Katalog.410.4001.Available from: https://www.bps.go.id/publication/2021/12/21/c3fd9f27372f6ddcf7462006/statistik-penduduk-lanjut-usia-2021.html
Zhao C, Wong L, Zhu Q, Yang H. Prevalence and correlates of chronic diseases in an elderly population: A community-based survey in Haikou. Forloni G, editor. PLOS ONE. 2018 Jun 14;13(6):e0199006.
Su SY, Lee LT, Lee WC. Mortality trends in chronic liver disease and cirrhosis from 1981 to 2015 in Taiwan. Popul Health Metr. 2021 Dec;19(1):36.
Kim IH, Kisseleva T, Brenner DA. Aging and liver disease: Curr Opin Gastroenterol. 2015 May;31(3):184–91.
Tajiri K. Liver physiology and liver diseases in the elderly. World J Gastroenterol. 2013;19(46):8459.
Stahl EC, Haschak MJ, Popovic B, Brown BN. Macrophages in the Aging Liver and Age-Related Liver Disease. Front Immunol. 2018 Nov 30;9:2795.
de Castro TG, Manickavasagan H, Muñoz SJ. Liver Disease in the Elderly. In: Handbook of Liver Disease [Internet]. Elsevier; 2018 [cited 2022 Apr 21]. p. 351–61. Available from: https://linkinghub.elsevier.com/retrieve/pii/B9780323478748000262
Hunt NJ, Kang SW (Sophie), Lockwood GP, Le Couteur DG, Cogger VC. Hallmarks of Aging in the Liver. Comput Struct Biotechnol J. 2019;17:1151–61.
Baiocchi L, Glaser S, Francis H, Kennedy L, Felli E, Alpini G, et al. Impact of Aging on Liver Cells and Liver Disease: Focus on the Biliary and Vascular Compartments. Hepatol Commun. 2021 Jul;5(7):1125–37.
Rana MV, Bonasera LK, Bordelon GJ. Pharmacologic Considerations of Anesthetic Agents in Geriatric Patients. Anesthesiol Clin. 2017 Jun;35(2):259–71.
Waring RH, Harris RM, Mitchell SC. Drug metabolism in the elderly: A multifactorial problem? Maturitas. 2017 Jun;100:27–32.
Benedetti M, Whomsley R, Canning M. Drug metabolism in the paediatric population and in the elderly. Drug Discov Today. 2007 Aug;12(15–16):599–610.
Mitchell SJ, Hilmer SN. Drug-induced liver injury in older adults. Ther Adv Drug Saf. :13.
Cao G, Jing W, Liu J, Liu M. The global trends and regional differences in incidence and mortality of hepatitis A from 1990 to 2019 and implications for its prevention. Hepatol Int. 2021 Oct;15(5):1068–82.
Brown GR, Persley K. Hepatitis A Epidemic in the Elderly. :8.
Lemon SM, Ott JJ, Van Damme P, Shouval D. Type A viral hepatitis: A summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2018 Jan;68(1):167–84.
Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, et al. Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020 Jul 3;69(5):1–38.
Muljono DH. Epidemiology of Hepatitis B and C in Republic of Indonesia. :5.
Alavi M, Grebely J, Hajarizadeh B, Amin J, Larney S, Law MG, et al. Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. BMC Infect Dis. 2018 Dec;18(1):215.
Kondo Y, Tsukada K, Takeuchi T, Mitsui T, Iwano K, Masuko K, et al. High carrier rate after hepatitis B virus infection in the elderly. Hepatology. 1993 Oct;18(4):768–74.
Carrion AF, Martin P. Viral Hepatitis in the Elderly. Am J Gastroenterol. 2012 May;107(5):691–7.
Liu J, Yang H, Lee M, Lu S, Jen C, Wang L, et al. Incidence and Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance: A Community-Based Follow-Up Study. Gastroenterology. 2010 Aug;139(2):474–82.
Yang HI, Lu SN, Wang LY, Chen CJ. Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med. 2002;7.
Zauli D, Crespi C, Fusconi M, Bonazzf L, Bianchi FB, Pisi E. Different Course of Acute Hepatitis B in Elderly Adults. J Gerontol. 1985 Jul 1;40(4):415–8.
Chu C. Prevalence of HBV precore/core promoter variants in the United States. Hepatology. 2003 Sep;38(3):619–28.
Chen CJ, Yang HI, Iloeje UH, The REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009 May;49(S5):S72–84.
Iloeje UH, Yang H, Su J, Jen C, You S, Chen C. Predicting Cirrhosis Risk Based on the Level of Circulating Hepatitis B Viral Load. Gastroenterology. 2006 Mar;130(3):678–86.
Kawaoka T, Suzuki F, Akuta N, Suzuki Y, Arase Y, Sezaki H, et al. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol. 2007 May 25;42(5):395–401.
Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Which Patients With Chronic Hepatitis B Are More Likely to Relapse After Interferon Alpha-Induced Hepatitis B e Antigen Loss in Korea?: J Clin Gastroenterol. 2004 Feb;38(2):124–9.
Cook JM, Gualde N, Hessel L, Mounier M, Michel JP, Denis F, et al. Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol. 1987 Oct;109(1):89–96.
Tohme RA, Awosika-Olumo D, Nielsen C, Khuwaja S, Scott J, Xing J, et al. Evaluation of hepatitis B vaccine immunogenicity among older adults during an outbreak response in assisted living facilities. Vaccine. 2011 Nov;29(50):9316–20.
Looney RJ, Hasan MS, Coffin D, Campbell D, Falsey AR, Kolassa J, et al. Hepatitis B Immunization of Healthy Elderly Adults: Relationship between Na¨ıve CD4ϩ T Cells and Primary Immune Response and Evaluation of GM-CSF as an Adjuvant. J Clin Immunol. 2001;21(1):7.
Cruciani M, Mengoli C, Serpelloni G, Mazzi R, Bosco O, Malena M. Granulocyte macrophage colony-stimulating factor as an adjuvant for hepatitis B vaccination: A meta-analysis. Vaccine. 2007 Jan;25(4):709–18.
Qureshi K, Petersen T, Andres J. Hepatitis C Treatment Differences in Elderly Patients: Single-Center Retrospective Study. Ann Pharmacother. 2020 Feb;54(2):113–21.
Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, et al. Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease? Am J Gastroenterol. 2006 Jun;101(6):1260–7.
Minola E, Prati D, Suter F, Maggiolo F, Caprioli F, Sonzogni A, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood. 2002 Jun 15;99(12):4588–91.
Yen HH, Su PY, Liu IL, Zeng YY, Huang SP, Hsu YC, et al. Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients. PeerJ. 2021 Mar 16;9:e10944.
Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016 Oct;44(8):856–65.
Pellicelli AM, Pace Palitti V, Vignally P, Moretti A, Tarquini P, Scifo G, et al. Impact of different Sofosbuvir-based direct acting antiviral (DAA) regimen in elderly cirrhotic patients: A real world experience from CLEO Group. Dig Liver Dis. 2016 Feb;48:e42.
Kamel S, Elessawy H, Ashraf O, Elbaz A, Dabbous H, El-Sayed M, et al. Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients. Gastroenterol Insights. 2021 Jul 17;12(3):336–46.
Takakusagi S, Takagi H, Kosone T, Sato K, Kakizaki S, Uraoka T. Prognosis of late elderly patients with chronic hepatitis C after achieving a sustained viral response by direct‐acting antivirals. JGH Open. 2021 Jan;5(1):122–7.
Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ. ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. Am J Gastroenterol. 2014 Jul;109(7):950–66.
Lucena MI, Sanabria J, García-Cortes M, Stephens C, Andrade RJ. Drug-induced liver injury in older people. Lancet Gastroenterol Hepatol. 2020 Sep;5(9):862–74.
Pedraza L, Laosa O, Rodríguez-Mañas L, Gutiérrez-Romero DF, Frías J, Carnicero JA, et al. Drug Induced Liver Injury in Geriatric Patients Detected by a Two-Hospital Prospective Pharmacovigilance Program: A Comprehensive Analysis Using the Roussel Uclaf Causality Assessment Method. Front Pharmacol. 2021 Feb 5;11:600255.
Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, Presentation, and Outcomes in Patients With Drug-Induced Liver Injury in the General Population of Iceland. Gastroenterology. 2013 Jun;144(7):1419-1425.e3.
Stine JG, Sateesh P, Lewis JH. Drug-Induced Liver Injury in the Elderly. Curr Gastroenterol Rep. 2013 Jan;15(1):299.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clin Pharmacol Ther. 2011 Jun;89(6):806–15.
Licata A. Adverse drug reactions and organ damage: The liver. Eur J Intern Med. 2016 Mar;28:9–16.
Andrade RJ, Aithal GP, Björnsson ES, Kaplowitz N, Kullak-Ublick GA, Larrey D, et al. EASL Clinical Practice Guidelines: Drug-induced liver injury. J Hepatol. 2019 Jun;70(6):1222–61.
Sandhu N, Navarro V. Drug‐Induced Liver Injury in GI Practice. Hepatol Commun. 2020 May;4(5):631–45.
Puoti C. New insights on hepatocellular carcinoma: epidemiology and clinical aspects. Hepatoma Res. 2018 Sep 21;4(9):57.
Macias RIR, Monte MJ, Serrano MA, González-Santiago JM, Martín-Arribas I, Simão AL, et al. Impact of aging on primary liver cancer: epidemiology, pathogenesis and therapeutics. Aging. 2021 Oct 15;13(19):23416–34.
Cho E, Cho HA, Jun CH, Kim HJ, Cho SB, Choi SK. A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes. In Vivo. 2019;33(5):1411–20.
Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for Hepatocellular Carcinoma in Elderly Patients: A Literature Review. J Cancer. 2013;4(8):635–43.
Oishi K, Itamoto T, Kobayashi T, Oshita A, Amano H, Ohdan H, et al. Hepatectomy for Hepatocellular Carcinoma in Elderly Patients Aged 75 Years or More. J Gastrointest Surg. 2009 Apr;13(4):695–701.
Miyaaki H. Clinical characteristics of hepatocellular carcinoma in elderly patients. Oncol Lett [Internet]. 2011 Jul 5 [cited 2022 Jun 12]; Available from: http://www.spandidos-publications.com/10.3892/ol.2011.359
Tsujita E, Utsunomiya T, Yamashita Y, et al. Outcome of hepatectomy in hepatocellular carcinoma patients aged 80 years and older. Hepatogastroenterology. 2012;59(117):1553-1555. doi:10.5754/hge09485
Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, Uesaka K. The Short- and Long-Term Outcomes in Elderly Patients with Hepatocellular Carcinoma after Curative Surgery: A Case-Controlled Study with Propensity Score Matching. Eur Surg Res. 2018;59(5–6):380–90.
Tsuchiya K, Ohki T, Sato K, Kondo M, Toda N, Tagawa K. Efficacy of percutaneous radiofrequency ablation for hepatocellular carcinoma treatment in patients aged ≥80 years. Liver Res. 2020 Dec;4(4):206–11.
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jan;10(1):25–34.
Llovet JM, Hilgard P, de Oliveira AC, Forner A, Zeuzem S, Galle PR, et al. Sorafenib in Advanced Hepatocellular Carcinoma. N Engl J Med. 2008;13.
Federico P, Giunta EF, Pappalardo A, Tufo A, Marte G, Attademo L, et al. How to Treat Hepatocellular Carcinoma in Elderly Patients. Pharmaceuticals. 2021 Mar 8;14(3):233.
Article Metrics
Abstract View
: 49 times
Download : 14 times
DOI: 10.24871/253202462-69
Refbacks
- There are currently no refbacks.
